Kahr Medical

Privately held: no public share price · Israel

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
SIRP-alpha/4-1BBL fusion proteinProtein / enzyme therapeutic
Non-Small Cell Lung CancerColorectal Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 January 2026Topline resultDSP107Phase 2a dose-expansion cohort of NCT04440735 in MSS-CRC: topline results
KAHR Bio · Source ↗

Financial reports

No financial reports recorded.